ClinicalTrials.gg
CompletedNCT00327769Updated Jan 25, 2011

Faslodex Advanced Breast Cancer Local Chinese Study

A Phase 3 interventional study of Fulvestrant and Anastrozole in Advanced Breast Cancer, sponsored by AstraZeneca. Completed at 12 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-25.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Enrollment
21st of 94
234 · median 71
Started
2005
with 3 others
Phase 3
21 of 95
3 open now
Registered
22nd of 95
by date
Lead sponsor
18 of 95
AstraZeneca

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 21st largest by enrollment of the 94 interventional ones that give a count, is one of 4 that started in 2005, is one of 21 in phase 3, and was the 22nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of Faslodex as secondary-line treatment compared with Arimidex in oestrogen receptor positive postmenopausal advanced breast cancer.

03

Conditions studied

  • Advanced Breast Cancer

Browse trials for

Keywords

  • Advanced breast cancer
  • fulvestrant
  • anastrozole
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • advanced breast cancer with oestrogen receptor positive
  • Progression under anti-oestrogen therapy.

Exclusion criteria

Exclusion Criteria:

  • Life-threatening ; to anastrozole
  • >2 regimens of hormonotherapy for advanced breast cancer
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
234 participants (actual)

Study arms

  • Active comparator
    1

    Anastrozole

    Drug: Anastrozole

  • Experimental
    2

    Anastrozole + Fulvestrant

    Drug: Fulvestrant · Drug: Anastrozole

Interventions

  • 250 mg intramuscular injection

    Also known as: Faslodex, ZD9238

  • 1 mg tablet

    Also known as: Arimidex, ZD1033

06

What researchers measure

Primary outcomes

  1. Time to Disease Progression (TTP)

Secondary outcomes

  1. Objective Response Rate (ORR)

  2. Clinical Benefit Rate (CBR)

  3. Time to Treatment Failure (TTF)

  4. Safety & Tolerability.

07

Study locations

12 sites
  • Research Site
    Beijing, China
  • Research Site
    Dalian, China
  • Research Site
    Fuzhou, China
  • Research Site
    Guangzhou, China
  • Research Site
    Hankou, China
  • Research Site
    He Fei, China
  • Research Site
    Huangzhou, China
  • Research Site
    Ji Nan, China
  • Research Site
    Nanjing, China
  • Research Site
    Shanghai, China
  • Research Site
    Wuhan, China
  • Research Site
    Xi AN, China
08

References and documents

Publications

  • Xu B, Jiang Z, Shao Z, Wang J, Feng J, Song S, Chen Z, Gu K, Yu S, Zhang Y, Wang C, Zhang F, Yang J. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. Cancer Chemother Pharmacol. 2011 Jan;67(1):223-30. doi: 10.1007/s00280-010-1483-x. Epub 2010 Oct 12. PubMed 20938664 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2006
First posted
May 19, 2006
Start
Nov 2005
CompletionActual
Sep 2007
Last update
Jan 25, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00327769
Lead sponsor
AstraZeneca
First posted
May 19, 2006
Start date
Nov 2005
Completion
Sep 2007
Last update
Jan 25, 2011

Study contacts

Breast Cancer Established Brands Team Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion